Cheetham Ali, Picco Louisa, Barnett Anthony, Lubman Dan I, Nielsen Suzanne
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University Peninsula Campus, Frankston, Victoria, 3199, Australia.
Turning Point, Eastern Health, Richmond, Victoria, 3121, Australia.
Subst Abuse Rehabil. 2022 Jan 25;13:1-12. doi: 10.2147/SAR.S304566. eCollection 2022.
Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma acts as a meaningful barrier to treatment entry and treatment provision. In the context of dramatically rising opioid-related harms, it is critical that we understand the drivers of stigma and how it affects opioid use disorder treatment and policy. The aim of this narrative review is to discuss how opioid-related stigma impacts treatment provision and harm reduction, and provide potential strategies to reduce stigma at a social and structural level. We used the Framework for Integrating Normative Influences on Stigma (FINIS) to identify sources of opioid-related stigma at the macro (structural stigma), meso (public stigma) and micro (internalised stigma) levels. Reducing stigma requires strategies that target multiple levels, however addressing inequity in the laws, regulations, and rules that segregate people with opioid and other substance use disorders from mainstream society is essential.
非法药物使用障碍是全球最受污名化的健康状况,污名是治疗准入和治疗提供的重大障碍。在与阿片类药物相关的危害急剧增加的背景下,我们了解污名的驱动因素以及它如何影响阿片类药物使用障碍的治疗和政策至关重要。本叙述性综述的目的是讨论与阿片类药物相关的污名如何影响治疗提供和减少危害,并提供在社会和结构层面减少污名的潜在策略。我们使用整合污名规范影响框架(FINIS)来识别宏观(结构污名)、中观(公众污名)和微观(内化污名)层面与阿片类药物相关的污名来源。减少污名需要针对多个层面的策略,然而解决将患有阿片类药物和其他物质使用障碍的人与主流社会隔离开来的法律、法规和规则中的不平等至关重要。